RxDoctor Payments Data

Richard Gerber, MD

Interventional Cardiology · Salinas, CANPI 1407854599

Payments from drug & device makers

$6,609in general payments, 2019–2025

Across 286 payments — averaging $23.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abiomed$582
  • Philips North America LLC$557
  • E.r. Squibb & Sons, L.L.C.$553
  • Novartis$471
  • Abbott$424
  • Novo Nordisk$391
  • plus $4K from 37 others

What the payments were for

  • Food & beverage$6,49698%
  • Education$1132%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,609 in reported general payments places this provider in the 35th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California

Medicare billing

Part B allowed, 2024
$332,190
Medicare patients
1,461
Services billed
4,008

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban280$263,680
EntrestoSacubitril/Valsartan234$254,168
XareltoRivaroxaban147$157,861
Repatha SureclickEvolocumab120$136,017
JardianceEmpagliflozin114$109,314
FarxigaDapagliflozin Propanediol87$68,359
Praluent PenAlirocumab36$38,641
VascepaIcosapent Ethyl41$24,583
VerquvoVericiguat12$15,127
OzempicSemaglutide14$14,197
Ezetimibe389$14,197
Repatha PushtronexEvolocumab19$13,804
MultaqDronedarone Hcl16$12,961
NexletolBempedoic Acid15$12,211
BrilintaTicagrelor15$9,892

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$148$263,680280 claims
NovartisEntresto$471$254,168234 claims
Johnson & JohnsonXarelto$227$157,861147 claims
Boehringer IngelheimJardiance$265$109,314114 claims
AstraZenecaFarxiga, Brilinta$345$78,250102 claims
MerckVerquvo$232$15,12712 claims
Novo NordiskOzempic$391$14,19714 claims
Sanofi-aventis U.S. LLCMultaq$123$12,96116 claims
Esperion Therapeutics, Inc.Nexletol$63$12,21115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 585 interventional cardiology providers in California.

Other interventional cardiology in Salinas

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →